ES2096574T3 - Procedimiento para la preparacion enantioselectiva de (omega-1)-hidroxialquilxantinas. - Google Patents

Procedimiento para la preparacion enantioselectiva de (omega-1)-hidroxialquilxantinas.

Info

Publication number
ES2096574T3
ES2096574T3 ES90124746T ES90124746T ES2096574T3 ES 2096574 T3 ES2096574 T3 ES 2096574T3 ES 90124746 T ES90124746 T ES 90124746T ES 90124746 T ES90124746 T ES 90124746T ES 2096574 T3 ES2096574 T3 ES 2096574T3
Authority
ES
Spain
Prior art keywords
hidroxialquilxantinas
enantioselectiva
omega
procedure
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90124746T
Other languages
English (en)
Spanish (es)
Inventor
Werner Dr Aretz
Harald Dr Furrer
Ulrich Dr Gebert
Heinz-Joachim Hinze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2096574T3 publication Critical patent/ES2096574T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/002—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by oxidation/reduction reactions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES90124746T 1989-12-23 1990-12-19 Procedimiento para la preparacion enantioselectiva de (omega-1)-hidroxialquilxantinas. Expired - Lifetime ES2096574T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3942872A DE3942872A1 (de) 1989-12-23 1989-12-23 Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen

Publications (1)

Publication Number Publication Date
ES2096574T3 true ES2096574T3 (es) 1997-03-16

Family

ID=6396381

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90124746T Expired - Lifetime ES2096574T3 (es) 1989-12-23 1990-12-19 Procedimiento para la preparacion enantioselectiva de (omega-1)-hidroxialquilxantinas.

Country Status (9)

Country Link
US (3) US5310666A (de)
EP (1) EP0435152B1 (de)
JP (1) JP2726760B2 (de)
KR (1) KR0174542B1 (de)
AT (1) ATE145247T1 (de)
DE (2) DE3942872A1 (de)
DK (1) DK0435152T3 (de)
ES (1) ES2096574T3 (de)
GR (1) GR3021611T3 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942871A1 (de) * 1989-12-23 1991-06-27 Hoechst Ag R-(-)-1-(5-hydroxyhexyl)-3-methyl-7-propylxanthin, verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittel
US5648357A (en) * 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
CA2112239C (en) * 1992-03-04 2000-05-09 James A. Bianco Enantiomeric hydroxylated xanthine compounds
US5580874A (en) * 1992-03-04 1996-12-03 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
AU5957694A (en) * 1992-12-31 1994-08-15 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from dog dander and uses therefor
AU6092794A (en) * 1993-01-19 1994-08-15 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
CA2190511A1 (en) * 1994-05-16 1995-11-23 J. Peter Klein Asymmetric synthesis of chiral secondary alcohols
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
CN101027404A (zh) * 2004-08-26 2007-08-29 辉瑞大药厂 对映选择性生物转化制备蛋白酪氨酸激酶抑制剂中间体
MX2010009300A (es) 2008-02-29 2010-11-05 Concert Pharmaceuticals Inc Derivados de xantina substituidos.
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2473052A4 (de) 2009-09-02 2013-03-20 Concert Pharmaceuticals Inc Substituierte xanthinderivate
US9074233B2 (en) 2010-09-01 2015-07-07 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
US9085788B2 (en) 2010-09-01 2015-07-21 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
RU2740926C1 (ru) * 2020-09-02 2021-01-21 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Производные тиетансодержащих 1-бутил-3-метилксантинов, проявляющие антиоксидантную активность

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE23032C (de) * DAUCHE & P. DENIAUD in Nantes Hebelpresse zum mechanischen Festdrücken des Bodens und Deckels von Konservenbüchsen auf die cylindrischen Mäntel derselben
DE1235320B (de) * 1964-09-05 1967-03-02 Albert Ag Chem Werke Verfahren zur Herstellung von 1-(Oxoalkyl)-3, 7-dimethylxanthinen
DE1233405B (de) * 1964-09-05 1967-02-02 Albert Ag Chem Werke Verfahren zur Herstellung von 7-(Oxoalkyl)-1, 3-dimethylxanthinen
DE2330742C2 (de) * 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2402908C2 (de) * 1974-01-22 1982-12-02 Fa. Johann A. Wülfing, 4040 Neuss 7-(3-Oxobutyl)-1,3-di-(n-butyl)-xanthin und Verfahren zu seiner Herstellung
DE2929596A1 (de) * 1979-07-21 1981-02-05 Hoechst Ag Verfahren zur herstellung von oxoalkyl-xanthinen
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
DE8700523U1 (de) * 1987-01-13 1987-05-07 August Steinmeyer GmbH & Co KG, 72458 Albstadt Kugelgewindetrieb

Also Published As

Publication number Publication date
ATE145247T1 (de) 1996-11-15
DE59010566D1 (de) 1996-12-19
US5710272A (en) 1998-01-20
JP2726760B2 (ja) 1998-03-11
DK0435152T3 (da) 1997-04-21
US5472873A (en) 1995-12-05
KR0174542B1 (ko) 1999-02-01
KR910012260A (ko) 1991-08-07
US5310666A (en) 1994-05-10
EP0435152A2 (de) 1991-07-03
EP0435152B1 (de) 1996-11-13
EP0435152A3 (en) 1992-08-05
DE3942872A1 (de) 1991-06-27
JPH069633A (ja) 1994-01-18
GR3021611T3 (en) 1997-02-28

Similar Documents

Publication Publication Date Title
ES2096574T3 (es) Procedimiento para la preparacion enantioselectiva de (omega-1)-hidroxialquilxantinas.
AU8689591A (en) High acid system nutritional formulations
FI873672A0 (fi) Kompositioner innehaollande l-3,4-dihydroxifenylalanin.
DE3682208D1 (de) Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung.
ATE148892T1 (de) Absorbierende polymere, verfahren zu deren herstellung und deren verwendung
PH23978A (en) Process for the preparation of glycerophosphocholine and glycerophosphoethanolamine derivatives
GR3005239T3 (de)
SE8403567L (sv) Fres
IT1248961B (it) Supporto o ruota per autoveicoli
BG51041A3 (en) Process for the preparation of (s)- alpha- ethyl- 2- oxo- 1- pyrrolidineacetamide
BR9404776A (pt) Processo para a preparação de 2,2-difluorceteno silil acetais e processo para a preparação de ésteres de ácido alfa,alfa-diflúor-beta-sililóxi-1,3-dioxolano-4-propanóico
AU5629690A (en) Carboplatin composition
DE3773045D1 (de) Sockel fuer ein gebissmodell und verfahren zur herstellung eines gebissmodells.
AU1413788A (en) Dihydropyridinamides process for their preparation, and their use in medicaments
AU4482985A (en) Pyrro-1-yl-phenyl-dihydropyridazones
FR2526442B1 (fr) Production de glucose deshydrogenase et utilisation de l'enzyme obtenu dans la synthese enzymatique de la l-carnitine
DE3565535D1 (en) Process for the preparation of optically active 1,4-dihydropyridines
ZA86740B (en) Process for the preparation of 4-(2-methoxyethyl)-phenylglycidyl ether and/or metoprolol
BG46004A3 (en) Method for preparing optical active 2- chlor- 12- (3- dimethylamin- 2- methylpropyl)- 12h- dibenzo- (d, g) (1, 3, 6)- dioxazocini
Kent Issue IX: How can we improve the role of research and educate speech-language pathologists and audiologists to be competent users of research?
AU2758288A (en) Synergistic combination of decarboxylase inhibitors and l- dopa pellets
DE3882353D1 (de) Hustenstillende zusammensetzungen und ein verfahren zu deren herstellung.
AU7680187A (en) Epoxy oligosaccharides
ATE46315T1 (de) Verfahren zur herstellung optisch aktiver chinonderivate.
DK161021C (da) Analogifremgangsmaade til fremstilling af fluorerede diaminoheptynderivater eller farmaceutisk acceptable salte deraf

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 435152

Country of ref document: ES